Company intelligence / Profile preview

Algenex

Ownership: Private
Employees: ~27
Development stage: Commercial

Overview

Algenex has developed baculovirus-based expression platforms (TopBac and CrisBio) for recombinant protein production in insect cells and moth pupae, with at least one veterinary vaccine (FatrovaxRHD) authorized in the EU and UK and multiple additional animal health vaccines and diagnostic reagents in development.[1][4][5]

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant proteinBiologic
Industry: Veterinary

Drug pipeline

1 asset

FatrovaxRHD

Commercial

Indications: Rabbit hemorrhagic disease

Partnerships

Biokit (licensing agreement for insect-based production of human in vitro diagnostics)Multiple international pharmaceutical companies for animal vaccines and diagnostics (undisclosed partners)

Beyond the preview

Go deeper on Algenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algenex.

Explore the full profile